Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3D Medicines Inc.
思路迪医药股份有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1244)

INSIDE INFORMATION
WITHDRAWAL OF CIVIL PROCEEDINGS BY QINGDAO HAINUO

Reference is made to the announcements of the Company dated January 24, 2025, February 17, 2025, July 2, 2025, and July 14, 2025, regarding the civil proceedings initiated by Qingdao Hainuo against the Group. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the aforementioned announcements.

On June 27, 2025, Qingdao Hainuo applied to the Court to withdraw the civil proceedings. The Company is pleased to announce that on July 22, 2025, the Company received a civil ruling dated July 18, 2025 issued by the Court. Pursuant to the ruling, the Court has approved the withdrawal of the civil proceedings by Qingdao Hainuo. The court fees and preservation order fees (amounting to approximately RMB1.17 million in aggregate) associated with the proceedings will be borne by Qingdao Hainuo.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong
July 22, 2025

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Jinqiao, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.